Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051688 · ClinicalTrials.gov registry record · Phase 2
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Chiron Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00051688: Clinical Trial Phase 2 study, sponsored by Chiron Corporation.
NCT00051688 is a Phase 2 study that was terminated before completion, run by Chiron Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051688, a Phase 2 study, was terminated before completion, sponsored by Chiron Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
Interventions
- DRUG oxaliplatin
- DRUG tezacitabine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Why NCT00051688 stopped before completion
NCT00051688 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00051688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00051688 about?
NCT00051688 is a clinical study titled "Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer". The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.
What is the current status of trial NCT00051688?
This trial is currently terminated. It is a Phase 2 study. The study started on 2003-06. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00051688?
The interventions under investigation include: oxaliplatin (DRUG), tezacitabine (DRUG).
Who is sponsoring clinical trial NCT00051688?
This trial is sponsored by Chiron Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia